Mezzion Pharma saw the highest growth of 0.66% in patent filings and no patents were granted in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.66% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Mezzion Pharma’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Mezzion Pharma has been focused on protecting inventions in European Patent Office(EPO) with two publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 50% of filings. The European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Mezzion Pharma is filings its patents..
Roche and Johnson & Johnson could be the strongest competitors for Mezzion Pharma
Patents related to rare diseases lead Mezzion Pharma's portfolio
Mezzion Pharma has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Congestive heart failure (heart failure) related patents lead Mezzion Pharma portfolio
Mezzion Pharma has highest number of patents in congestive heart failure (heart failure).
For comprehensive analysis of Mezzion Pharma's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

